Clinical efficacy of psoralen + sunlight vs. combination of isotretinoin and psoralen + sunlight for the treatment of chronic plaque‐type psoriasis vulgaris: a randomized hospital‐based study

Gahalaut, Pratik; Soodan, Puneet Singh; Mishra, Nitin; Rastogi, Madhur Kant; Soodan, Hardev Singh; Chauhan, Suvarcha

doi:10.1111/phpp.12125

Cited by 15 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients were then started on oral PUVAsol therapy. In the absence of a standard protocol for PUVAsol, the most frequently followed protocol was selected which is described below [ 15 ]. For oral PUVAsol, 8-methoxypsoralen (8-MOP) was administered orally in morning with breakfast followed by sunlight exposure, after an interval of 2 hours on 3 alternate days in a week.…”

Section: Methodsmentioning

confidence: 99%

Effect of Oral PUVAsol on the Quality of Life in Indian Patients Having Chronic Plaque Psoriasis

Gahalaut

Mishra

Soodan

et al. 2014

Dermatology Research and Practice

Self Cite

View full text Add to dashboard Cite

Background. Psoriasis is associated with a high impact on health-related QoL (quality of life). PUVAsol has been successfully used for treating psoriasis instead of standard PUVA therapy in developing countries. However, data for PUVAsol therapy and its effect on QoL in psoriatic patients is meagre. Objective. To investigate the effect of PUVAsol on the quality of life in patients having chronic plaque psoriasis. Materials and Methods. An observational prospective study done in patients having chronic plaque psoriasis. PASI and DLQI were calculated before initiating treatment with oral PUVAsol. These were compared with the respective scores after 12 weeks of regular treatment with PUVAsol. Statistical analysis was done using SPSS version 20.0. Results. Both PASI and DLQI showed statistically significant reduction after 12 weeks of regular treatment. 90% of patients responded favourably to PUVAsol therapy in the study and all the domains of DLQI showed significant reduction except domain of “work and school.” Conclusion. Our results show that regular PUVAsol treatment improves the physical appearance of disease as evident by decrease in PASI scores. It also improves the QoL of the patients. This study will add upon the growing evidence of efficacy of PUVAsol.

show abstract

Section: Methodsmentioning

confidence: 99%

Effect of Oral PUVAsol on the Quality of Life in Indian Patients Having Chronic Plaque Psoriasis

Gahalaut

Mishra

Soodan

et al. 2014

Dermatology Research and Practice

Self Cite

View full text Add to dashboard Cite

show abstract

“…Gahalaut et al 11 in a PP analysis of 40 patients of psoriasis treated with PUVA sol observed that 20 per cent of their patients achieved PASI 75, 40 per cent achieved PASI 50, while 10 per cent had an aggravation of their disease at 12 wk. The response of psoriasis to PUVA sol is enhanced by the concomitant use of retinoids 12 . Kar et al 13 reported complete clearance of CPP in 32 per cent patients and more than 50 per cent improvement in 44 per cent of patients treated with PUVA sol for eight weeks.…”

Section: Discussionmentioning

confidence: 99%

A non-inferiority randomized controlled clinical trial comparing Unani formulation & psoralen plus ultraviolet A sol in chronic plaque psoriasis

et al. 2018

View full text Add to dashboard Cite

Background & objectives:Though Unani medications have been used for centuries to treat psoriasis, there is paucity of published studies which have systematically evaluated their efficacy and safety. This study was conducted to establish non-inferiority of Unani medications (oral UNIM-401 and topical UNIM-403) vs psoralen plus ultraviolet A (PUVA) sol in treatment of moderate-severe chronic plaque psoriasis (CPP) in achieving psoriasis area severity index (PASI) 75 at 12 wk and to estimate proportion of patients who relapsed in follow up period of 12 weeks, after having achieved PASI 50.Methods:In this randomized, controlled trial patients with CPP were block randomized to receive either Unani treatment (147 patients) or PUVA sol (140 patients) for 12 weeks. Percentage reduction in PASI was determined in each patient at 12 wk to calculate number of patients who achieved PASI 75 as also to estimate median of percentage reduction in PASI in each group. All patients who achieved PASI 50 at 12 weeks were followed up for another 12 wk to determine proportion of patients who relapsed.Results:Of the 287 patients randomized, 84 of 147 in Unani group and 67 of 140 in PUVA sol group completed 12 weeks of treatment. On intention-to-treat (ITT) analysis, the response in patients on Unani medication was not inferior to those receiving PUVA sol, in attaining PASI 75 (16.3% in Unani group vs 15.7% in the PUVA sol group). Median of percentage reduction of PASI at 12 wk from baseline in Unani group (68.2%; −60, 100) and PUVA sol group (63%; −15.7, 100) was comparable. Proportion of patients who relapsed at 24 wk was comparable in both groups. However, frequency of clinical side effects was significantly higher (P =0.001) in PUVA sol group (16.4%) compared to Unani group (2%).Interpretation & conclusions:The findings of the present study indicated that oral UNIM-401 and topical UNIM-403 were effective and well tolerated therapeutic options in patients with moderate-severe CPP.

show abstract

“… 91 The second study showed that combining isotretinoin (0.5 mg/kg/day) with oral psoralen + sun exposure (PUVAsol) is more effective than PUVAsol alone for treating chronic plaque psoriasis. 92 A case series documented that five individuals with generalized pustular psoriasis did not respond to conventional therapy but were effectively treated with isotretinoin (1.5–2 mg/kg/day) within a short treatment period. 93 A comparative study revealed that even though the efficacy of isotretinoin and etretinate in treating generalized pustular psoriasis was comparable, isotretinoin was less effective than etretinate in treating chronic plaque psoriasis.…”

Section: Introductionmentioning

confidence: 99%

Oral Isotretinoin and Its Uses in Dermatology: A Review

Paichitrojjana,

Paichitrojjana

2023

DDDT

View full text Add to dashboard Cite

In 1982, the Food and Drug Administration (FDA) of the United States of America approved isotretinoin (13-cis-retinoic acid), a retinoid derivative of vitamin A, to treat severe recalcitrant acne vulgaris. Apart from its prescribed use for severe acne, evidence suggests that isotretinoin is commonly used off-label to treat mild-to-moderate acne, inflammatory skin conditions, genodermatoses, skin cancer, and other skin disorders. This is due to its anti-inflammatory, immunomodulatory, and antineoplastic properties. Some “off-label” use is successful, while others are ineffective. Therefore, this information is essential to clinicians for deciding on the appropriate use of isotretinoin. In this article, we aim to review the most updated evidence-based data about the use of oral isotretinoin in dermatology.

show abstract

Clinical efficacy of psoralen + sunlight vs. combination of isotretinoin and psoralen + sunlight for the treatment of chronic plaque‐type psoriasis vulgaris: a randomized hospital‐based study

Abstract: The combination of isotretinoin with PUVAsol is more effective compared with PUVAsol alone for treating chronic plaque psoriasis.

Cited by 15 publications

References 30 publications

Effect of Oral PUVAsol on the Quality of Life in Indian Patients Having Chronic Plaque Psoriasis

Effect of Oral PUVAsol on the Quality of Life in Indian Patients Having Chronic Plaque Psoriasis

A non-inferiority randomized controlled clinical trial comparing Unani formulation & psoralen plus ultraviolet A sol in chronic plaque psoriasis

Oral Isotretinoin and Its Uses in Dermatology: A Review

Contact Info

Product

Resources

About